語系:
繁體中文
English
說明(常見問題)
登入
回首頁
切換:
標籤
|
MARC模式
|
ISBD
Immunotherapy of hepatocellular carc...
~
SpringerLink (Online service)
Immunotherapy of hepatocellular carcinoma
紀錄類型:
書目-語言資料,印刷品 : Monograph/item
正題名/作者:
Immunotherapy of hepatocellular carcinoma/ edited by Tim F. Greten.
其他作者:
Greten, Tim F.
出版者:
Cham :Springer International Publishing : : 2017.,
面頁冊數:
x, 167 p. :ill., digital ; : 24 cm.;
Contained By:
Springer eBooks
標題:
Liver - Cancer -
電子資源:
http://dx.doi.org/10.1007/978-3-319-64958-0
ISBN:
9783319649580
Immunotherapy of hepatocellular carcinoma
Immunotherapy of hepatocellular carcinoma
[electronic resource] /edited by Tim F. Greten. - Cham :Springer International Publishing :2017. - x, 167 p. :ill., digital ;24 cm.
Preface -- Introduction -- Vaccine approaches -- Spontaneous Immune responses to ablative therapies -- Antigen-specific T cell responses. Immune checkpoint inhibitors -- NASH and HCC -- Cytokine activated killer cells -- Sorafenib combination therapy -- Glypican 3 -- Suppressor cells -- Cytokines in HCC pathogenesis and treatment -- Index.
In this book we provide insights into liver - cancer and immunology. Experts in the field provide an overview over fundamental immunological questions in liver cancer and tumorimmunology, which form the base for immune based approaches in HCC, which gain increasing interest in the community due to first promising results obtained in early clinical trials. Hepatocellular carcinoma (HCC) is the third most common cause of cancer related death in the United States. Treatment options are limited. Viral hepatitis is one of the major risk factors for HCC, which represents a typical "inflammation-induced" cancer. Immune-based treatment approaches have revolutionized oncology in recent years. Various treatment strategies have received FDA approval including dendritic cell vaccination, for prostate cancer as well as immune checkpoint inhibition targeting the CTLA4 or the PD1/PDL1 axis in melanoma, lung, and kidney cancer. Additionally, cell based therapies (adoptive T cell therapy, CAR T cells and TCR transduced T cells) have demonstrated significant efficacy in patients with B cell malignancies and melanoma. Immune checkpoint inhibitors in particular have generated enormous excitement across the entire field of oncology, providing a significant benefit to a minority of patients.
ISBN: 9783319649580
Standard No.: 10.1007/978-3-319-64958-0doiSubjects--Topical Terms:
1171677
Liver
--Cancer
LC Class. No.: RC280.L5
Dewey Class. No.: 616.9943606
Immunotherapy of hepatocellular carcinoma
LDR
:02565nam a2200313 a 4500
001
904918
003
DE-He213
005
20180419142526.0
006
m d
007
cr nn 008maaau
008
190308s2017 gw s 0 eng d
020
$a
9783319649580
$q
(electronic bk.)
020
$a
9783319649573
$q
(paper)
024
7
$a
10.1007/978-3-319-64958-0
$2
doi
035
$a
978-3-319-64958-0
040
$a
GP
$c
GP
041
0
$a
eng
050
4
$a
RC280.L5
072
7
$a
MBGR
$2
bicssc
072
7
$a
MED000000
$2
bisacsh
082
0 4
$a
616.9943606
$2
23
090
$a
RC280.L5
$b
I33 2017
245
0 0
$a
Immunotherapy of hepatocellular carcinoma
$h
[electronic resource] /
$c
edited by Tim F. Greten.
260
$a
Cham :
$c
2017.
$b
Springer International Publishing :
$b
Imprint: Springer,
300
$a
x, 167 p. :
$b
ill., digital ;
$c
24 cm.
505
0
$a
Preface -- Introduction -- Vaccine approaches -- Spontaneous Immune responses to ablative therapies -- Antigen-specific T cell responses. Immune checkpoint inhibitors -- NASH and HCC -- Cytokine activated killer cells -- Sorafenib combination therapy -- Glypican 3 -- Suppressor cells -- Cytokines in HCC pathogenesis and treatment -- Index.
520
$a
In this book we provide insights into liver - cancer and immunology. Experts in the field provide an overview over fundamental immunological questions in liver cancer and tumorimmunology, which form the base for immune based approaches in HCC, which gain increasing interest in the community due to first promising results obtained in early clinical trials. Hepatocellular carcinoma (HCC) is the third most common cause of cancer related death in the United States. Treatment options are limited. Viral hepatitis is one of the major risk factors for HCC, which represents a typical "inflammation-induced" cancer. Immune-based treatment approaches have revolutionized oncology in recent years. Various treatment strategies have received FDA approval including dendritic cell vaccination, for prostate cancer as well as immune checkpoint inhibition targeting the CTLA4 or the PD1/PDL1 axis in melanoma, lung, and kidney cancer. Additionally, cell based therapies (adoptive T cell therapy, CAR T cells and TCR transduced T cells) have demonstrated significant efficacy in patients with B cell malignancies and melanoma. Immune checkpoint inhibitors in particular have generated enormous excitement across the entire field of oncology, providing a significant benefit to a minority of patients.
650
0
$a
Liver
$x
Cancer
$x
Immunotherapy.
$3
1171677
650
1 4
$a
Biomedicine.
$3
593880
650
2 4
$a
Biomedicine general.
$3
668531
700
1
$a
Greten, Tim F.
$3
1171676
710
2
$a
SpringerLink (Online service)
$3
593884
773
0
$t
Springer eBooks
856
4 0
$u
http://dx.doi.org/10.1007/978-3-319-64958-0
950
$a
Biomedical and Life Sciences (Springer-11642)
筆 0 讀者評論
多媒體
評論
新增評論
分享你的心得
Export
取書館別
處理中
...
變更密碼[密碼必須為2種組合(英文和數字)及長度為10碼以上]
登入